Multiplex Assay Kit for Sclerostin (SOST) ,etc. by FLIA (Flow Luminescence Immunoassay) 
VBCH; Sclerosteosis
(Note: Up to 8-plex in one testing reaction)
- UOM
- FOB US$ 437.00 US$ 454.00 US$ 479.00 US$ 512.00 US$ 546.00 US$ 596.00 US$ 672.00 US$ 840.00
- Quantity
Overview
Properties
- Product No.LMC864Hu
- Organism SpeciesHomo sapiens (Human) Same name, Different species.
- ApplicationsFLIA Kit for Antigen Detection.
Research use only - DownloadInstruction Manual
- CategoryDevelopmental science
Sign into your account
Share a new citation as an author
Upload your experimental result
Review
Contact us
Please fill in the blank.
-
Packages (Simulation)
-
Packages (Simulation)
-
Results demonstration
-
Typical Standard Curve
-
ISO9001: 2008, ISO13485: 2003 Registered
Recovery
Matrices listed below were spiked with certain level of recombinant Sclerostin (SOST) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Sclerostin (SOST) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.
| Matrix | Recovery range (%) | Average(%) |
| serum(n=5) | 80-101 | 84 |
| EDTA plasma(n=5) | 94-105 | 102 |
| heparin plasma(n=5) | 89-99 | 94 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Sclerostin (SOST) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Sclerostin (SOST) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Sclerostin (SOST) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
| Sample | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 89-96% | 86-101% | 83-102% | 92-105% |
| EDTA plasma(n=5) | 90-103% | 85-105% | 98-105% | 94-105% |
| heparin plasma(n=5) | 79-92% | 99-105% | 93-105% | 79-89% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
| Reagents | Quantity | Reagents | Quantity |
| 96-well plate | 1 | Plate sealer for 96 wells | 4 |
| Pre-Mixed Standard | 2 | Standard Diluent | 1×20mL |
| Pre-Mixed Magnetic beads (22#:SOST) | 1 | Analysis buffer | 1×20mL |
| Pre-Mixed Detection Reagent A | 1×120μL | Assay Diluent A | 1×12mL |
| Detection Reagent B (PE-SA) | 1×120μL | Assay Diluent B | 1×12mL |
| Sheath Fluid | 1×10mL | Wash Buffer (30 × concentrate) | 1×20mL |
| Instruction manual | 1 |
Assay procedure summary
1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.
Test principle
Analyte-specific antibodies are pre-coated onto color-coded microparticles. Microparticles, standards, and samples are pipetted into wells and the immobilized antibodies bind the analytes of interest. After washing away any unbound substances, a biotinylated antibody cocktail specific to the analytes of interest is added to each well. Following a wash to remove any unbound biotinylated antibody, Streptavidin-Phycoerythrin conjugate (Streptavidin-PE), which binds to the biotinylated detection antibodies, is added to each well. A final wash removes unbound Streptavidin-PE and the microparticles are resuspended in buffer and read using the Luminex or Bio-Plex analyzer.The MFI developed is proportional to the concentration of analytes of interest in the sample.
Giveaways
Increment services
Citations
- Exendin-4 Increases Bone Mineral Density in Type 2 Diabetic OLETF Rats Potentially Through the Down-Regulation of SOST/Sclerostin in OsteocytesPubMed: 23357248
- Acute effects of glucocorticoids on serum markers of osteoclasts, osteoblasts, and osteocytesPubmed: 23247536
- Serum Sclerostin in Adult High-Activity Patients with Juvenile Idiopathic ArthritisPubmed:Pmc4236454
- Early effects of tumor necrosis factor inhibition on bone homeostasis after soluble tumor necrosis factor receptor usePubmed:Pmc4219971
- The Anti-Osteoanabolic Function of Sclerostin is Blunted in Mice Carrying a High Bone Mass Mutation of Lrp5Pubmed:25640331
- DMP-1-mediatedPubMed: 26481310
- Effect of Mirtazapine on Rat Bone Tissue after OrchidectomyPubMed: 25871861
- The effect of levetiracetam on rat bone mineral density, bone structure and biochemical markers of bone metabolismPubmed:29428468
- EFFECTS OF DISEASE-MODIFYING ANTIRHEUMATIC DRUG TREATMENT ON PERIARTICULAR BONE REMODELING IN RHEUMATOID AND PSORIATIC …:
- Dobesity: relationship between vitamin d deficiency, obesity and sclerostin as a novel biomarker of bone metabolism
- Circulating Osteocyte‐Related Biomarkers (vitamin D, sclerostin, dickkopf-1), hepcidin, and oxidative stress markers in early breast cancer: their impact in …Pubmed: 33065276
- Long-Term Administration of Abacavir and Etravirine Impairs Semen Quality and Alters Redox System and Bone Metabolism in Growing Male Wistar Rats34373766